


AMENDMENTS TO THE CLAIMS

CLAIMS

1. **(Currently Amended)** A method for the treatment or prophylaxis of parasitic infections, such as malaria, in man or a zoonose vector comprising the administration of an effective amount of a compound of formula I to a patient in need thereof, or to the vector~~Use of a compound according to formula I, in the manufacture of a medicament for the treatment or prophylaxis of parasitic infections in mammals, including man:~~



where

R¹ is H, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R⁴;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH-, -C≡C-, -NR⁵-;

R⁴ is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy, C₁-C₅ alkanoyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkylthio, -N(C₀-C₃-alkyl)₂, hydroxymethyl, aminomethyl, carboxymethyl; -SO₂N(C₀-C₃-alkyl), -SO₂C₁-C₅-alkyl;

R⁵ is H, C₁-C₄ alkyl, C₁-C₄ alkanoyl;

E is Si or C;

R⁶, R⁷ and R⁸ are independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S,

R⁶, R⁷ and R⁸ are independently optionally substituted with R⁴;

G is -O-, -S-, -CHR¹⁰-, -C(=O)-;

J is -CH₂-, or when G is CHR¹⁰ may also be -O- or -NH-;

R¹⁰ is H, F, -CH₃, -CH₂NH₂, -CH₂OH, -OH; or a pharmaceutically acceptable ether, amide or ester thereof

R¹¹ is H, F, -CH₃, -CH₂NH₂, -CH₂OH, CH(OH)CH₃, CH(NH₂)CH₃; or a pharmaceutically acceptable ether, amide or ester thereof; or

R¹⁰ and R¹¹ together define an olefinic bond, or together form a -CH₂-group, thereby defining a *cis* or *trans* cyclopropyl group;

and pharmaceutically acceptable salts thereof.

2. ~~Use of a compound~~The method according to claim 1, wherein G is -O- or -CH₂-.

3. ~~Use of a compound~~The method according to claim 1 wherein R¹⁰ and R¹¹ define an olefinic bond or a cyclopropyl group.

4. **(Currently Amended)** ~~The method~~Use of a compound according to claim 1, wherein R¹¹ is H; CH₂OH or a pharmaceutically acceptable ether or ester thereof; or CH₂NH₂ or a pharmaceutically acceptable amide thereof.


5. **(Currently Amended)** ~~The method~~Use of a compound according to claim 1, wherein R¹ is H.

6. **(Currently Amended)** ~~The method~~Use of a compound according to claim 1, wherein D is -O- or -NH-.

7. **(Currently Amended)** ~~The method~~Use of a compound according to claim 6, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is oxymethylene, oxyethylene or oxypropylene.

8. **(Currently Amended)** ~~The method~~Use of a compound according to claim 6, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is aminomethylene, aminoethylene or aminopropylene.

9. **(Currently Amended)** ~~Use of a compound~~ The method according to claim 1, wherein at least two of R⁶, R⁷ and R⁸ are aryl.
10. **(Currently Amended)** ~~The method~~ Use of a compound according to claim 1, wherein R⁶ is optionally substituted phenyl.
11. **(Currently Amended)** ~~The method~~ Use of a compound according to claim 10 wherein R⁸ is optionally substituted phenyl or pyridyl.
12. **(Currently Amended)** ~~The method~~ Use of a compound according to claim 1 wherein E is C.
13. **(Currently Amended)** ~~The method~~ Use according to any preceding claim, wherein the zoonose vector is a parasite is ~~and~~ a Plasmodium species.
14. **(Currently Amended)** A compound of the formula II:



where

R¹ is H, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R⁴;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH-, -C≡C-, -NR⁵-;

R⁴ is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkyloxy, C₁-C₅ alkanoyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkylthio, -N(C₀-C₃-alkyl)₂, hydroxymethyl, aminomethyl, carboxymethyl; -SO₂N(C₀-C₃-alkyl), -SO₂C₁-C₅-alkyl;

R⁵ is H, C₁-C₄-alkyl, C₁-C₄-alkanoyl;

E is Si or C;

R⁶ and R⁷ are independently selected from a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature wherein each ring has 0 to 3 heteroatoms selected from N, O and S
R⁸ is selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R⁶, R⁷ and R⁸ are independently optionally substituted with R⁴;

G is -O-, -S-, -CHR¹⁰-, -C(=O)-;

J is -CH₂-, or when G is CHR¹⁰ may also be -O- or -NH-;

R¹⁰ is H, F, -CH₃, -CH₂NH₂, -CH₂OH, ~~-OH~~; or a pharmaceutically acceptable ether, amide or ester thereof;

R¹¹ is H, F, -CH₃, -CH₂NH₂, ~~-CH₂OH~~, CH(OH)CH₃, CH(NH₂)CH₃ or a pharmaceutically acceptable ether, amide or ester thereof; or


R¹⁰ and R¹¹ together define an olefinic bond, or together form a -CH₂-group, thereby defining a *cis* or *trans* cyclopropyl group;
and pharmaceutically acceptable salts thereof.

15. (Original) A compound according to claim 14 wherein G is -O- or -CH₂-.

16. (Original) A compound according to claim 14 wherein R¹⁰ and R¹¹ define an olefinic bond or a cyclopropyl group.

17. (Original) A compound according to claim 14, wherein R¹¹ is H; CH₂OH or a pharmaceutically acceptable ether or amide thereof, or CH₂NH₂ or a pharmaceutically acceptable amide thereof.

- Rule 1.126 18. **(Original)** A compound according to claim 14, wherein R¹ is H.
19. ~~20.~~ **(Original)** A compound according to claim 14, wherein D is -O- or -NH-.
20. ~~21.~~ **(Original)** A compound according to claim 20, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is oxymethylene, oxyethylene or oxypropylene.
21. ~~22.~~ **(Original)** A compound according to claim 20, wherein C₀-C₃-alkylene-D-C₀-C₃-alkylene is aminomethylene, aminoethylene or aminopropylene.
22. ~~23.~~ **(Original)** A compound according to claim 14, wherein R⁶ is optionally substituted phenyl.
23. ~~24.~~ **(Original)** A compound according to claim 23 wherein R⁸ is optionally substituted phenyl or pyridyl.
24. ~~25.~~ **(Original)** A compound according to claim 14 wherein E is C.
25. ~~26.~~ **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in any preceding claim 1 and a pharmaceutically acceptable carrier or diluent therefore.
26. ~~27.~~ **(NEW)** A compound of the formula II:



II

where

R¹ is H, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R⁴;

D is -NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH-, -C≡C-, -NR⁵-;

R⁴ is hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkyloxy, C₁-C₅ alkanoyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkylthio, -N(C₀-C₃-alkyl)₂, hydroxymethyl, aminomethyl, carboxymethyl; -SO₂N(C₀-C₃-alkyl), -SO₂C₁-C₅-alkyl;

R⁵ is H, C₁-C₄-alkyl, C₁-C₄-alkanoyl;

E is Si or C;

R⁶ and R⁷ are independently selected from a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature wherein each ring has 0 to 3 heteroatoms selected from N, O and S

R⁸ is selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R⁶, R⁷ and R⁸ are independently optionally substituted with R⁴;

G is -S-, -CHR¹⁰-, -C(=O)-;

J is -CH₂-, or when G is CHR¹⁰ J may also be -O- or -NH-;

R¹⁰ is H, F, -CH₃, -CH₂NH₂, -CH₂OH; or a pharmaceutically acceptable ether, amide or ester thereof

R¹¹ is CH₂OH; or a pharmaceutically acceptable ether, amide or ester thereof; or

R¹⁰ and R¹¹ together define an olefinic bond, or together form a -CH₂-group, thereby defining a *cis* or *trans* cyclopropyl group;
and pharmaceutically acceptable salts thereof.